2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Sunday, November 10, 2019

4:30PM-6:00PM: Abstract Number: 951

Avoidable Acute Care Use for Vaccine-Preventable Illnesses Among Medicaid Beneficiaries with Lupus: Demographic and Healthcare Utilization Differences

3S089: Health Services Research I: Clinical Perspectives (951–956)

4:30PM-6:00PM: Abstract Number: 883

B Cell-specific MyD88 Regulates Pathology After Disease Onset in Murine Lupus

3S100: B Cell Biology & Targets in Autoimmune & Inflammatory Disease (880–885)

4:30PM-6:00PM: Abstract Number: 904

Bone Manifestations in Gaucher Disease: A Monocentric Study of 128 Patients

3S104: Miscellaneous Rheumatic & Inflammatory Disease I: Expanding the Spectrum of Clinical Features in Rheumatological Disorders (903–908)

4:30PM-6:00PM: Abstract Number: 912

Co-morbidities Associated with Discordance Between Structural Severity and Pain in Osteoarthritis: Implications for Clinical Trial Design in OA – a Post-Hoc Analysis of Data from Two Randomized Controlled Trials

3S106: Osteoarthritis – Clinical I: Innovations (909–914)

4:30PM-6:00PM: Abstract Number: 945

Comparison of Clinical Manifestations in IgG4 Related Disease Patients with/without Aortitis/Periaortitis and Periarteritis: A Prospective Cohort Study of 587 Patients with IgG4-RD Disease

3S112: Vasculitis – Non-ANCA-Associated & Related Disorders I: Miscellaneous Disorders (945–950)

4:30PM-6:00PM: Abstract Number: 887

Critical Role of the Cholinergic System Involvement in Osteoarthritis

3S105: Osteoarthritis & Joint Biology – Basic Science (886–891)

4:30PM-6:00PM: Abstract Number: 913

Depression as a Moderator of Analgesic Effectiveness in Knee Osteoarthritis

3S106: Osteoarthritis – Clinical I: Innovations (909–914)

4:30PM-6:00PM: Abstract Number: 916

Development and Initial Validation of the MS Score for Diagnosis of Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis

3S107: Pediatric Rheumatology – Clinical I: Systemic JIA (915–920)

4:30PM-6:00PM: Abstract Number: 915

Development and Initial Validation of the Systemic JADAS, a New Composite Disease Activity Score for Systemic Juvenile Idiopathic Arthritis

3S107: Pediatric Rheumatology – Clinical I: Systemic JIA (915–920)

4:30PM-6:00PM: Abstract Number: 880

Diseased Lupus Nephritis Kidneys Serve as a Primary Site of Systemic Autoimmune Development

3S100: B Cell Biology & Targets in Autoimmune & Inflammatory Disease (880–885)

4:30PM-6:00PM: Abstract Number: 937

Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Ankylosing Spondylitis: 48-Week Efficacy and Safety Results from a Phase 2b, Randomized, Blinded, Placebo-Controlled, Dose-Ranging Study

3S111: Spondyloarthritis Including Psoriatic Arthritis – Clinical II: Axial Spondyloarthritis Treatment (933–938)

4:30PM-6:00PM: Abstract Number: 936

Earlier Treatment of Non-Radiographic Axial Spondyloarthritis with Certolizumab Pegol Results in Improved Clinical and Patient-Reported Outcomes

3S111: Spondyloarthritis Including Psoriatic Arthritis – Clinical II: Axial Spondyloarthritis Treatment (933–938)

4:30PM-6:00PM: Abstract Number: 944

Efficacy and Safety of Dapirolizumab Pegol in Patients with Moderately to Severely Active Systemic Lupus Erythematosus: A Randomized, Placebo-Controlled Study

3S110: SLE – Clinical III: Clinical Trials II (939–944)

4:30PM-6:00PM: Abstract Number: 932

Efficacy and Safety of E6011, an Anti-Fractalkine Monoclonal Antibody, in MTX-IR Patients with Rheumatoid Arthritis

3S109: RA – Treatments II: Novel Treatments for RA (927–932)

4:30PM-6:00PM: Abstract Number: 929

Efficacy and Safety of Fenebrutinib, a BTK Inhibitor, Compared to Placebo in Rheumatoid Arthritis Patients with Active Disease Despite TNF Inhibitor Treatment: Randomized, Double Blind, Phase 2 Study

3S109: RA – Treatments II: Novel Treatments for RA (927–932)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].